Factor IX inhaled gene therapy

Drug Profile

Factor IX inhaled gene therapy

Alternative Names: Factor IX gene therapy inhalation - Copernicus Therapeutics

Latest Information Update: 25 Mar 2008

Price : $50

At a glance

  • Originator Copernicus Therapeutics
  • Class Gene therapies
  • Mechanism of Action Factor IX stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Haemophilia B

Most Recent Events

  • 25 Mar 2008 Preclinical development is ongoing
  • 04 Dec 2003 No development reported - Preclinical for Haemophilia B in USA (Inhalation)
  • 08 Oct 2001 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top